# Presentation: 007646

##  
Anna D. Barker, Ph.D.
Deputy Director, National Cancer Institute
National Cancer Advisory Board Meeting
June 14, 2006

** **
**Anna D. Barker, Ph.D.**
- Deputy Director, National Cancer Institute
- National Cancer Advisory Board Meeting
**June 14, 2006**

- NCI Alliance for Nanotechnology in Cancer:Research Advances and Development of Clinical Applications

## The Potential of Nanotechnology

**Nanotechnology** has the potential to be the key enabler for the transition of molecular-based science into the clinic, facilitating major advances in the early detection, diagnosis, and treatment of cancer.

## Detection, Treatment, Prevention: Nanotech from Bench to Bedside 

- Detection, Treatment, Prevention: Nanotech from Bench to Bedside

**Target Identification and**
**Validation**

**Lead Development**

- High Content
- Cellular Assays

- Real-time therapeutic monitoring

- High sensitivity
- Gene/protein detection

**Animal**** ****Studies**

**Patient**
**Care**

- Multifunctional Targeted Nanoparticles

- Real-time Therapeutic Monitoring

- Ultrasensitive Biomarker Detection

- Contrast and Optical Imaging Agents

**Clinical Trials**

**Early Detection**

**Diagnosis**

**Treatment**

## NCI Strategic Approach to Nanotech

**Early investments**
- Novel technologies through the Unconventional Innovations Program since 1998
**Counsel from the community**
- Input from the scientific, cancer research and advocacy communities
**Planning a comprehensive effort**
- Cancer Nanotechnology Plan to drive systems-level change and catalyze product development
**Launch of the Alliance**
- NCI Alliance for Nanotechnology in Cancer in 2004
**Milestone-driven execution**
- Defined programs; collaborators; milestones; reporting processes

## NCI Alliance for Nanotechnologyin Cancer

**Goals:**
- Research tools to identify new biological targets
- Agents to monitor predictive molecular changes and prevent precancerous cells from becoming malignant
- Imaging agents and diagnostics to detect cancer in earliest, most easily treatable, pre-symptomatic stage
- Multifunctional targeted devices to deliver multiple therapeutic agents directly to cancer cells
- Systems to provide real-time assessments of therapeutic and surgical efficacy
- Novel methods to manage symptoms that reduce quality of life

## NCI Nanotech Alliance Programs

-  Centers of Cancer Nanotechnology Excellence
-  Nanotechnology Platforms for Cancer Research
-  Multidisciplinary Research Teams
- Training
- Interagency Collaborations
-  Nanotechnology Characterization Laboratory

## NCI Nanotech Alliance Program Awards

**Centers of Cancer Nanotechnology Excellence (8)**
**Cancer Nanotechnology Platform Partnerships (12)**

**Nanotechnology Platform for Targeting Solid Tumors, **The Sidney Kimmel Cancer Center, San Diego, Calif.

**Detecting Cancer Early with Targeted Nano-probes for Vascular Signatures**,** **University of California, San Francisco, Calif.

**Nanotechnology Platform for Pediatric Brain Cancer Imaging and Therapy**, University of Washington, Seattle, Wash.

**Near-Infrared Fluorescence Nanoparticles for Targeted Optical Imaging**University of Texas M. D. Anderson Cancer Center, Houston, Texas

**Hybrid Nanoparticles in Imaging and Therapy of Prostate Cancer**, University of Missouri, Columbia, Mo.

**DNA-linked Dendrimer Nanoparticle Systems for Cancer Diagnosis and Treatment**, University of Michigan, Ann Arbor, Mich.

**Metallofullerene Nanoplatform for Imaging and Treating Infiltrative Tumor**, Virginia Commonwealth University, Richmond, Va.

**Novel Cancer Nanotechnology Platforms for Photodynamic Therapy and Imaging**, Roswell Park Cancer Institute, Buffalo, N.Y.
**Multifunctional Nanoparticles in Diagnosis and Therapy of Pancreatic Cancer**, State University of New York, Buffalo, N.Y.

**Integrated System for Cancer Biomarker Detection, **Massachusetts Institute of Technology, Cambridge, Mass.

**Nanotherapeutic Strategy for Multidrug Resistant Tumors**, Northeastern University, Boston, Mass.
**Photodestruction of Ovarian Cancer:  ErbB3 Targeted Aptamer-Nanoparticle Conjugate**, Massachusetts General Hospital, Boston, Mass.

**Carolina Center of Cancer Nanotechnology Excellence, **University of North Carolina, Chapel Hill, N.C.

**Nanosystems Biology Cancer Center**, California Institute of Technology, Pasadena, Calif.

**Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer**, University of California, San Diego, Calif.

**Emory-Georgia Tech Nanotech-nology Center for Personalized and Predictive Oncology**, Atlanta, Ga.

**Nanomaterials for Cancer Diagnostics and Therapeutics**, Northwestern University, Evanston, Ill.

**The Siteman Center of Cancer Nanotechnology Excellence at Washington University**, St. Louis, Mo.

**Center for Cancer Nanotechnology Excellence Focused on Therapy Response**, Stanford University, Palo Alto, Calif.

**MIT-Harvard Center of Cancer Nanotechnology Excellence**, Cambridge, Mass.

## NCI-NSF Nanobiotechnology Collaboration:  Training the Next Generation

- NCI-NSF Nanobiotechnology Collaboration:  Training the Next Generation

**IGERT Training Grants (4)**

**Building Leadership for the Nanotechnology Workforce of Tomorrow**, University of Washington, Seattle, WA – *Marjorie Olmstead, PI*

**NanoPharmaceutical Engineering and Science**, Rutgers University, New Brunswick, NJ – *Fernando Muzzio, PI*

**Nanomedical Science and Technology**, Northeastern University, Boston, MA – *Srinivas Sridhar, PI*

**Integrative Nanoscience and Microsystems, **University of New Mexico, Albuquerque, NM – *Diana Huffaker, PI*

## Interagency Collaborations

**Training **
**Dissemination ****of Results**

**Public Interface**
**Interpret Data on Environment, Health and Safety**

**Shared Data and Platforms**

**Standards/Precision Measurement Capabilities**

## NCL Role:
Interface with CCNEs, individual investigators, NIST and FDA to develop standards and characterization data for nanoscale materials 
Perform preclinical toxicology, pharmacology, and efficacy testing of nanoscale devices
Formulate and validate protocols for physical, in vitro, and ADME/tox characterization of nanoparticles

- Interface with CCNEs, individual investigators, NIST and FDA to develop standards and characterization data for nanoscale materials
- Perform preclinical toxicology, pharmacology, and efficacy testing of nanoscale devices
- Formulate and validate protocols for physical, *in vitro*, and ADME/tox characterization of nanoparticles

- Nanotechnology Characterization Laboratory (NCL)

## Novel Attributes of the NCI Nanotech Alliance

- Steady interaction among Alliance participants and the community through:
- Governance Committee
- Continual evaluation of project programs through performance milestones
- Teleconferences
- Technology Transfer, Intellectual Property, and Communications Working Groups
- Website with “Knowledge Environment” and secure Intranet for Alliance members
- Advocacy involvement on an ongoing basis

## NCI Nanotech Alliance:The Challenge and Deliverables

- Produce tangible solutions which are clinically applicable, in a short period of time
- Medical community expects significant advances:
- Where solutions are currently non-existent
- Where replacement technologies are superior to existing methods
- Identify “early successes”
- Program as viable addition to existing NCI funding portfolio:
- Well interconnected
- Truly produces a paradigm change